FDA Issues Emergency Use Authorization for Topical Powder to Prevent and Treat New World Screwworm in Multiple Species

Print

Washington, D.C., April 27, 2026 —Today, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for the prevention and treatment of New World screwworm (NWS) infestations (myiasis).

The FDA has concluded that based on the scientific evidence available, it is reasonable to believe that Negasunt Powder may be effective for the prevention and treatment of NWS myiasis in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids (e.g., mules), and captive wild, exotic, and zoo mammals, and that the known and potential benefits of the product outweigh its known and potential risks.

Read More